Increased bone remodeling in first-episode major depressive disorder

Area of Science:

• Endocrinology
• Psychiatry
• Bone Metabolism

Background:

• Depressive disorder is associated with reduced bone mineral density.
• Pathogenic mechanisms in early-stage depression-related bone loss require elucidation.
• The role of bone remodeling markers in first-episode depression is not fully understood.

Purpose of the Study:

• To evaluate biochemical bone remodeling markers in patients with their first depressive episode.
• To investigate potential pathogenic mechanisms of bone mineral density loss in early depression.
• To assess bone turnover in relation to psychotropic medication status.

Main Methods:

• Measured serum levels of osteocalcin, parathyroid hormone, bone alkaline phosphatase, telopeptide, collagen type I C-terminal propeptide, cross-laps, and 25-hydroxyvitamin D.
• Determined serum cortisol and interleukin-6 levels.
• Assessed 19 patients with a single depressive episode and 19 age-matched healthy controls using the Schedules for Clinical Assessment in Neuropsychiatry interview.

Main Results:

• Depressed patients exhibited elevated osteoblastic (osteocalcin) and osteoclastic (telopeptide, cross-laps) markers.
• Lower parathyroid hormone levels were observed in depressed patients.
• Higher serum cortisol was found in depressed patients, but no correlation with bone markers was identified.

Conclusions:

• Increased bone remodeling, independent of vitamin D deficiency, appears to contribute to calcium release from bone in depression.
• Inhibition of parathyroid hormone secretion is suggested as a consequence of elevated bone remodeling.
• These findings highlight altered bone metabolism in early-stage depression.